Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report

Excess fibroblast growth factor 23 (FGF23) causes hypophosphatemic osteomalacia, which is associated with impaired bone matrix mineralization. Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by over-secretion of FGF23 from a tumor. Burosumab, a fully human monoclonal antibo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Bone Rep
Main Authors: Miyaoka, Daichi, Imanishi, Yasuo, Yano, Masahiro, Toi, Norikazu, Nagata, Yuki, Kurajoh, Masafumi, Yamada, Shinsuke, Morioka, Tomoaki, Emoto, Masanori
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7701316/
https://ncbi.nlm.nih.gov/pubmed/33294501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bonr.2020.100736
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados